Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EBIT: 2020-2025

Historic EBIT for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$61.2 million.

  • 4D Molecular Therapeutics' EBIT fell 19.66% to -$61.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year decrease of 36.82%. This contributed to the annual value of -$187.8 million for FY2024, which is 66.43% down from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' EBIT is -$61.2 million, which was down 2.91% from -$59.5 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' EBIT's 5-year high stood at -$7.6 million during Q2 2021, with a 5-year trough of -$61.2 million in Q3 2025.
  • Moreover, its 3-year median value for EBIT was -$42.5 million (2024), whereas its average is -$43.2 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' EBIT skyrocketed by 49.86% in 2021 and then crashed by 274.22% in 2022.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' EBIT stood at -$24.8 million in 2021, then dropped by 15.97% to -$28.7 million in 2022, then decreased by 27.62% to -$36.7 million in 2023, then tumbled by 53.11% to -$56.1 million in 2024, then decreased by 19.66% to -$61.2 million in 2025.
  • Its EBIT stands at -$61.2 million for Q3 2025, versus -$59.5 million for Q2 2025 and -$53.6 million for Q1 2025.